Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial

Sonja Zweegman, Fredrik H. Schjesvold, Bronno van der Holt, Mark-David Levin, Claudia A. M. Stege, Anders Waage, Maria B. L. Leijs, Saskia K. Klein, Damian L. Szatkowski, Per Axelsson, Trung Hieu Do, Dorota Knut-Bojanovska, Ellen van der Spek, Asta Svirskaite, Pino Poddighe, Marian Stevens-Kroef, Markus Hansson, Niels W. C. J. van de Donk, Einar Haukas, Pieter SonneveldNiels Abildgaard

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
JournalBlood
Volume132
Issue numberSuppl. 1
Pages (from-to)800-800
Number of pages1
ISSN0006-4971
DOIs
Publication statusPublished - Nov 2018
Event60th ASH Annual Meeting & Exposition - San Diego, United States
Duration: 1 Dec 20184 Dec 2018
Conference number: 60

Conference

Conference60th ASH Annual Meeting & Exposition
Number60
Country/TerritoryUnited States
CitySan Diego
Period01/12/201804/12/2018

Cite this